142 related articles for article (PubMed ID: 28830934)
41. A nude mouse model of obesity to study the mechanisms of resistance to aromatase inhibitors.
Schech A; Yu S; Goloubeva O; McLenithan J; Sabnis G
Endocr Relat Cancer; 2015 Aug; 22(4):645-56. PubMed ID: 26113604
[TBL] [Abstract][Full Text] [Related]
42. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
43. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase.
Bartholomeusz C; Gonzalez-Angulo AM; Kazansky A; Krishnamurthy S; Liu P; Yuan LX; Yamasaki F; Liu S; Hayashi N; Zhang D; Esteva FJ; Hortobagyi GN; Ueno NT
Clin Cancer Res; 2010 Mar; 16(6):1802-11. PubMed ID: 20215547
[TBL] [Abstract][Full Text] [Related]
44. Hyperinsulinemia Promotes Esophageal Cancer Development in a Surgically-Induced Duodeno-Esophageal Reflux Murine Model.
Arcidiacono D; Dedja A; Giacometti C; Fassan M; Nucci D; Francia S; Fabris F; Zaramella A; Gallagher EJ; Cassaro M; Rugge M; LeRoith D; Alberti A; Realdon S
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662006
[TBL] [Abstract][Full Text] [Related]
45. Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity.
Lue H; Thiele M; Franz J; Dahl E; Speckgens S; Leng L; Fingerle-Rowson G; Bucala R; Lüscher B; Bernhagen J
Oncogene; 2007 Aug; 26(35):5046-59. PubMed ID: 17310986
[TBL] [Abstract][Full Text] [Related]
46. TRIM28 multi-domain protein regulates cancer stem cell population in breast tumor development.
Czerwińska P; Shah PK; Tomczak K; Klimczak M; Mazurek S; Sozańska B; Biecek P; Korski K; Filas V; Mackiewicz A; Andersen JN; Wiznerowicz M
Oncotarget; 2017 Jan; 8(1):863-882. PubMed ID: 27845900
[TBL] [Abstract][Full Text] [Related]
47. Obesity-associated Breast Cancer: Analysis of risk factors.
Engin A
Adv Exp Med Biol; 2017; 960():571-606. PubMed ID: 28585217
[TBL] [Abstract][Full Text] [Related]
48. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
[TBL] [Abstract][Full Text] [Related]
49. Eriocalyxin B, a novel autophagy inducer, exerts anti-tumor activity through the suppression of Akt/mTOR/p70S6K signaling pathway in breast cancer.
Zhou X; Yue GG; Chan AM; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Biochem Pharmacol; 2017 Oct; 142():58-70. PubMed ID: 28669564
[TBL] [Abstract][Full Text] [Related]
50. Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts.
Wang J; Chen P; Mrkobrada M; Hu M; Vallis KA; Reilly RM
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1273-80. PubMed ID: 12640557
[TBL] [Abstract][Full Text] [Related]
51. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
52. How to inhibit breast cancer and breast cancer metastasis with Akt inhibitors: Lessons learned from studies in mice.
Hay N
J Breast Cancer Res; 2021; 1(2):30-33. PubMed ID: 35578699
[TBL] [Abstract][Full Text] [Related]
53. Strategies to target the cancer driver MYC in tumor cells.
Weber LI; Hartl M
Front Oncol; 2023; 13():1142111. PubMed ID: 36969025
[TBL] [Abstract][Full Text] [Related]
54. PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.
Galiger C; Dahlhaus M; Vitek MP; Debatin KM; Beltinger C
Front Oncol; 2022; 12():744984. PubMed ID: 35814385
[TBL] [Abstract][Full Text] [Related]
55. TMEM176B Regulates AKT/mTOR Signaling and Tumor Growth in Triple-Negative Breast Cancer.
Kang C; Rostoker R; Ben-Shumel S; Rashed R; Duty JA; Demircioglu D; Antoniou IM; Isakov L; Shen-Orr Z; Bravo-Cordero JJ; Kase N; Cuajungco MP; Moran TM; LeRoith D; Gallagher EJ
Cells; 2021 Dec; 10(12):. PubMed ID: 34943938
[TBL] [Abstract][Full Text] [Related]
56. Hyperinsulinemia in Obesity, Inflammation, and Cancer.
Zhang AMY; Wellberg EA; Kopp JL; Johnson JD
Diabetes Metab J; 2021 May; 45(3):285-311. PubMed ID: 33775061
[TBL] [Abstract][Full Text] [Related]
57. Obesity, Type 2 Diabetes, and Cancer Risk.
Scully T; Ettela A; LeRoith D; Gallagher EJ
Front Oncol; 2020; 10():615375. PubMed ID: 33604295
[TBL] [Abstract][Full Text] [Related]
58. Hyperinsulinaemia in cancer.
Gallagher EJ; LeRoith D
Nat Rev Cancer; 2020 Nov; 20(11):629-644. PubMed ID: 32908223
[TBL] [Abstract][Full Text] [Related]
59. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
Allen-Petersen BL; Sears RC
BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
[TBL] [Abstract][Full Text] [Related]
60. Hyperinsulinemia promotes aberrant histone acetylation in triple-negative breast cancer.
Senapati P; Kato H; Lee M; Leung A; Thai C; Sanchez A; Gallagher EJ; LeRoith D; Seewaldt VL; Ann DK; Schones DE
Epigenetics Chromatin; 2019 Jul; 12(1):44. PubMed ID: 31315653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
